COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.

Denmark-based UNION therapeutics has bought LEO Pharma’s PDE4 inhibitor compound series for use in developing treatments for psoriasis and atopic dermatitis.

Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.

The UK biotech will have no problems funding a Phase III program for its nebulized first-in-class COPD therapy ensifentrine as investors old and new flocked to buy into the stock.